Inclusion Criteria:

- Refractory to conventional antineoplastic treatment or no standard therapy option
available

- ECOG Performance Status score of < 2

- Agreement not to take vitamin E products such as Juvela (except for over-the-counter
[OTC] and diet supplements).

Exclusion Criteria:

- Patients treated with other unapproved drugs/investigational drugs, chemotherapy,
biological response modifiers, immunotherapy or endocrinotherapy within 4 weeks prior
to entry in this study or nitrosoureas within 6 weeks before initial dosing of SH
U04722

- Patients on concurrent therapy with warfarin or coumarin derivatives.

- Patients who had radiation therapy within 2 weeks prior to entry into this study.

- Patients with a history of serious hypersensitivity to taxanes.

- Patients with current peripheral neuropathy (? Common Terminology Criteria for
Adverse Events [CTCAE] Grade 2)